CHEPLAPHARM Arzneimittel GmbH


This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.


Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit


The latest from CHEPLAPHARM



CHEPLAPHARM engaged DKSH to market its regional business in several Asian countries

Zurich (CH) / Greifswald (DE), December 15, 2017 – In a formal ceremony at the DKSH headquarters in Zurich, DKSH and CHEPLAPHARM Arzneimittel GmbH have signed a strategic partnership for a regional…

more chevron_right


CHEPLAPHARM reached the final phase of the Axia Awards

According to the motto “We are creating a future with perspectives”, mid-sized companies were honored for their sustainable and successful management by Deloitte and WirtschaftsWoche, together with…

more chevron_right


CHEPLAPHARM plans further investments

On the occasion of the visit of the German Chancellor Angela Merkel and the Minister of Economics Harry Glawe at CHEPLAPHARM in Greifswald, CEO Sebastian F. Braun announces further investments of 210…

more chevron_right


Mysimba®: Commercialization and distributorship arrangement with Orexigen Therapeutics Ireland, Ltd.

The wholly owned subsidiary of Orexigen Therapeutics, Inc. (OREX), and CHEPLAPHARM Arzneimittel GmbH have executed a distributorship agreement covering Germany, France and Austria for Mysimba®…

more chevron_right


50 new employees: CHEPLAPHARM’s successful story continues

The successful company from Greifswald, CHEPLAPHARM Arzneimittel GmbH, continues to grow: 50 new employees have been recruited in the past eight months.

more chevron_right


Largest private sector investment in Mecklenburg-Western Pomerania: CHEPLAPHARM makes the megadeal

With an investment of approximately 340 million euros, CHEPLAPHARM Arzneimittel GmbH breaks all private sector records in Mecklenburg-Western Pomerania and moves into the big league for medium-sized…

more chevron_right


CHEPLAPHARM acquires product rights for ANEXATE® from F. Hofmann-La Roche

Amount of investment in the mid, double-digit million euro range. CHEPLAPHARM creates eight new jobs with this acquisition.

more chevron_right


CHEPLAPHARM assumes Italian rights for ALDACTONE®

CHEPLAPHARM acquired the product rights for the prescription medication ALDACTONE® in Italy on 09.11.2015, thus boosting its presence within this market that is very important to CHEPLAPHARM.

more chevron_right


CHEPLAPHARM moves into new 2500 square meter office building at Greifswald’s Business Park Ziegelhof

more chevron_right


CHEPLAPHARM Arzneimittel GmbH launches 100 million EURO investment program

more chevron_right

Investor Relations topics

Back to top expand_less